Stem cells: a primer
Although bone marrow-derived stem cells, particularly hematopoietic stem cells (HSC), have been studied for half a century and have curative application for hematologic diseases and inborn errors of metabolism, science is currently experiencing a new wave of enthusiasm for stem cell biology and its potential for regenerative medicine.
A stem cell, loosely defined, is a self-renewing progenitor cell that can generate at least one cell type that can reconstitute the function of its tissue of origin. In vertebrates, embryonic stem cells (ESC) derived from the inner cell mass of blastocysts 1,2 selfrenew and are totipotent, with the ability to generate all differentiated somatic cell types. 3, 4 Despite disagreement over the ethics of ESC science, these cells offer the greatest potential to revolutionize biomedicine, although many technical challenges remain. In turn, ESCs generate organ or tissue-specific stem cells. Although not totipotent, a number of adult pluripotent stem cell populations that express properties similar to stromal cells first isolated from marrow by Dexter et al. 5, 6 have recently been derived in vitro, including multipotent adult progenitor cells derived from adherent bone marrow, human bone marrow-derived multipotent stem cells, unrestricted somatic stem cells, marrow-isolated adult multilineage inducible cells and skin-derived precursors (all reviewed in 7 ) . These cells are all capable of differentiation into cells belonging to more than one germ layer. However, at present it is unknown if these populations can be derived in vivo and additional studies are required to define their therapeutic potential. Recently, embryonic-like stem cells that express markers of pluripotent stem cells have been isolated from mouse marrow 8 and human cord blood. 9 The potential of pluripotent stem cells stem cells as a source of pluripotent stem cells may offer an alternative to ESCs.
Adult stem cells, such as HSC or neural stem cells are not totipotent and can yield only a single or limited number of cell types restricted to the tissue of origin. Adult stem and progenitor cells have potential therapeutic applications for numerous serious diseases for which no current therapy exists. Adult stem cells function to repair injured tissues 10, 11 and unlike ESC can be found in essentially every organ and tissue. Evidence also suggests that after local tissue stem cells are exhausted by injury, they can be repopulated/supplemented by bone marrow-derived cells. 10, 12, 13 Skeletal muscle cells or satellite cells are normally quiescent but upon injury generate myoblasts and new satellite cells. 14, 15 These cells have been reported to give rise to cells in different lineages including blood stem cells, [16] [17] [18] [19] however it remains to be determined whether these stem cells truly demonstrate plasticity, that is, trans-differentiation. 20, 21 Neural stem cells derived from neurospheres can self-renew and differentiate into functional neurons, oligodendrocytes and astrocytes. 22, 23 Additional studies suggest that neural stem cells can contribute to blood lineages, 24, 25 but there has been difficulty in reproducing this effect. 26 Adult mesenchymal stem cells are adherent nonhematopoietic cells isolated from bone marrow, fat, umbilical cord blood or placenta. They can be propagated for a limited number of passages and can differentiate into bone, cartilage, fat and myoblasts, 27, 28 as well as neurons and astrocytes. [28] [29] [30] The most widely studied adult stem cells are the hematopoietic stem cells. These cells can be isolated from bone marrow, umbilical cord blood, fetal liver or bone marrow and mobilized peripheral blood and posses the ability to self-renew throughout life and differentiate to populate all blood cell lineages. A great deal of controversy exists regarding the transdifferentiation capacity of HSC. Most in vivo studies showing multilineage differentiation used unmarked mixed cell populations making it impossible to unequivocally evaluate plasticity. However, several studies using single cells have shown multilineage repopulation 31, 32 although the lack of definitive markers for donor cells, lack of functional analysis, the rarity of events and the unexpected contribution of cell fusion, leave us with uncertainty regarding the contribution of HSC to nonhematopoietic tissues.
Not all hematopoietic stem cells are created equal
Although all populations of hematopoietic stem cells possess the capacity to self-renew and differentiate, not all HSC populations behave the same. Differences in engraftment using HSC from different sources may reflect stem cell number, cell cycle status, 33, 34 presence or absence of facilitating or accessory cells 35, 36 or intrinsic differences in homing properties or proliferative capacity. 37, 38 This review will focus on the phenotype and function of mobilized hematopoietic stem cells, particularly those HSC mobilized by chemokine agonists and chemokine receptor antagonists, which can be rapidly mobilized and express engraftment properties that are distinct from resident marrow or cytokine mobilized stem cells.
Mobilized stem cells
Mobilized hematopoietic stem cells, that is, stem cells induced to exit marrow and traffic to peripheral blood in response to external stimuli, are now the primary source of stem cells for autologous and allogeneic hematopoietic transplantation. The initial observations that hematopoietic progenitor cells (HPC) were found in the blood of patients recovering from chemotherapy [39] [40] [41] lead to the realization that stem cells could be forced to exit marrow where they can be collected by apheresis and used for clinical transplantation. 42 Although a variety of agents can mobilize stem cells with different kinetics and efficiencies [43] [44] [45] and these agents can be additive or synergistic when used in combination, currently G-CSF is the predominant stem cell mobilizer used clinically based upon potency, predictability and safety. G-CSF-mobilized peripheral blood stem cells (PBSC) engraft earlier than bone marrow or umbilical cord blood stem cells, 42, [46] [47] [48] which translates into faster neutrophil and platelet recoveries, fewer platelet transfusions, faster lymphocyte reconstitution, fewer febrile episodes [49] [50] [51] [52] and superior total and disease-free survival. 53, 54 The superiority of G-CSF mobilized stem cells for transplantation leads to questions concerning quantity versus quality of the stem cell graft. Although total clonogenic cells in the mobilized graft often exceed marrow grafts, which could be responsible for enhanced engraftment, 55, 56 earlier engraftment has also been seen when equivalent numbers of stem/progenitor cells were transplanted, suggesting that the efficacy of mobilized stem cells may be attributable to quality of the stem cells. 57 However, although numerous studies describe differences in gene and protein expression patterns and function, at least in vitro, these qualitative differences have not led to an understanding of the enhanced engraftment properties of G-CSF mobilized stem cells. Recently, however, differential homing of G-CSF-mobilized stem cells resulting from enhanced motility and low CD26 expression relative to bone marrow stem cells have been suggested as contributing factors for enhanced engraftment. 58 
Chemokine and chemokine receptor-induced stem cell mobilization
Chemokines are a large family of cytokines that direct movement of leukocyte populations, including HSC and HPC. [59] [60] [61] Several chemokine receptors have been implicated in stem cell mobilization. Mobilization of HPC and short-term marrow repopulating cells has been demonstrated for macrophage inflammatory protein-1 (MIP-1a/CCL3), which is a ligand for both CCR1 and CCR5. 62, 63 The mobilization response of MIP1a appears to require the CCR1 receptor, 64 however its mechanism of action is unknown. Mobilization observed with SDF-1a peptide analogs, CTCE-0021 and CTCE-0214; 65, 66 the CXCR4 antagonist AMD3100 [67] [68] [69] and the SDF-1 analog Met-SDF-1b 70, 71 suggest that altering SDF1/CXCR4 signaling, most likely by CXCR4 receptor down modulation, 66, 70, 71 produces the response. Multiple ligands for the CXCR2 receptor, including IL-8/ CXCL8, the GRO proteins, particularly GROb/CXCL2 and GROb D4 /CXCL8 D4 and murine MIP-2 (KC), the murine homolog of IL-8 and/or GROb, all rapidly mobilize HSC and HPC in mice and/or monkeys (for review see 72, 73 ). In contrast to CXCR4, which is expressed on HSC and HPC, CXCR2 is not expressed on stem and progenitor cells, rather mobilization is mediated via proteases from CXCR2-positive neutrophils. 74, 75 Although these proteases ultimately impact the CXCR4/SDF-1 axis, it is not clear that this axis is a critical component of the stem cell mobilization response by CXC chemokines or their receptors.
Stem cell mobilization by hematopoietic cytokines like G-CSF and other growth factors or anti-integrin antibodies requires multiple daily dosing schedules for maximal efficacy. In contrast, mobilization by chemokines is rapid, generally being maximal at 1 h or less following administration. Mobilization of HPC by MIP1a, presumably through CCR1 and by CTCE-0021 and AMD3100, through antagonizing CXCR4, is maximal within 60 min post single administration, while mobilization by GROb, via CXCR2 is maximal at 15 min. Similarly, mobilization of HSC by CTCE-0021, AMD3100 and GROb occur with the same general kinetics as mobilization of HPC, although detailed specific differential analysis of HPC versus HSC mobilization has not been performed. An additional feature of chemokine mobilizers is that they mobilize in a greater than additive or synergistic fashion when combined with G-CSF. Highly synergistic mobilization of HPC is seen when MIP1a, CTCE-0021, AMD3100 or GROb are added as single bolus agents at the end of a standard G-CSF mobilization regimen (Table 1) . Combination use of chemokines alone without G-CSF also shows synergistic mobilization of HPC and even more dramatic mobilization synergy is seen with the use of combination chemokine mobilization after a standard regimen of G-CSF, for example the combination of GROb, MIP1a and G-CSF mobilized 42 fold more CFU-GM/ml blood than the combination of GROb plus MIP1a and 3-20-fold more CFU-GM than any agent used alone. However, mobilization of short-term repopulating cells does not a priori predict mobilization of HSC. Mobilization of long-term repopulating cells using chemokines and G-CSF has been studied most in the context of GROb and AMD3100. Immunophenotypic analysis of Sca-1 pos c-kit pos lineage neg (SKL) cells, which in mice contain the long-term repopulating stem cell population, clearly shows that the combinations of GROb or AMD3100 with G-CSF results in mobilization of 2.8-3.7-fold more HSC than the sum of each agent used alone.
Enhanced engraftment by chemokine-mobilized stem cells
Long-term reconstitution in mice using these combination chemokine plus G-CSF-mobilized PBSC is achieved with fewer cells, which could indicate that enhanced engraftment is solely a function of the number of mobilized stem and progenitor cells. However, when one compares engraftment using chemokine versus G-CSF mobilized PBSC, it becomes apparent that factors 
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other than stem and progenitor cell number are involved and that chemokine mobilized stem cells appear to be intrinsically superior to PBSC mobilized by G-CSF. 67, 73, 76, 77 In primary competitive transplant studies using whole mobilized low-density peripheral blood mononuclear cells (LDMC) and normal bone marrow in a 2:1 ratio in congenic mice (Figure 1 ), G-CSF, AMD3100 and GROb mobilized cells all contributed significantly to donor repopulation, with GRObmobilized cells producing significantly higher chimerism than cells mobilized by G-CSF or AMD3100. Significantly higher chimerism is observed using GROb plus G-CSF or AMD3100 plus G-CSF-mobilized cells. In general, the GROb and GROb plus G-CSF-mobilized grafts (2 Â 10 6 LDMC) contain twice the number of KSL and three times the number of CD34 neg KSL cells compared to G-CSF mobilized grafts. 77 The increased stem cell frequency in these grafts likely contributes to their superior performance compared to G-CSF-mobilized cells. In secondary transplant studies that test for stem cell self-renewal, repopulated marrow from the primary recipient at 6 months post transplant is transplanted into a lethally irradiated recipient in noncompetitive fashion, that is, without competitor cells. One would expect that the degree of chimerism in the second host would be identical to that in the primary host. This is in fact what is observed for G-CSF-mobilized cells. However, the marrow cells from mice receiving grafts mobilized by GROb or AMD3100 alone, or combination GROb or AMD3100 plus G-CSF-mobilized cells showed significantly higher contribution to chimerism of the mobilized stem cells than observed in the primary transplant. This unexpected finding indicates that the chemokine-mobilized grafts are inherently more competitive than marrow cells or G-CSF mobilized LDMC.
The enhanced engraftment properties of GROb-mobilized cells are also most apparent in the kinetics of white blood cell recoveries post-transplantation. Using grafts with equal cell number, lethally irradiated mice transplanted with GRObmobilized PB-LDMC routinely recover neutrophil counts In primary transplants, one half million marrow cells from BoyJ mice (CD45.1) were mixed with one million PBMC from C57Bl/6 mice (CD45.2) mobilized by G-CSF, GROb, AMD3100 or the combination of GROb or AMD3100 with G-CSF and transplanted into lethally irradiated C57Bl/6 mice. Chimerism in recipient mice was analyzed after 6 months. In secondary transplants, individual mice that had received transplants containing marrow and mobilized peripheral blood stem cells were killed and one million marrow cells transplanted in noncompetitive fashion to lethally irradiated C57Bl/6 mice. Chimerism was analyzed at 6 months post-transplant. *Po0.05 compared to G-CSF. 
Po0
.05 compared to G-CSF, GROb or AMD3100 alone, analyzed by ANOVA with Bonferroni correction.
z Po0.05 compared to GROb or AMD3100 plus G-CSF primary transplants, analyzed by ANOVA with Bonferroni correction.
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Leukemia SPOTLIGHT (ANC) 2 days, and platelet counts 7-13 days, earlier than mice transplanted with G-CSF-mobilized PB-LDMC. 76, 77 Even faster ANC recovery is observed using cells mobilized by the combination of GROb plus G-CSF, although platelet count recovery was somewhat delayed compared to GROb-mobilized cells transplanted alone, but still faster than with G-CSFmobilized PB-LDMC. The number of short-term repopulating cells transplanted does not explain these results, in fact, animals receiving the GROb-mobilized grafts generally received 60-80% fewer HPC than the G-CSF group.
Chemokine mobilized HSC are different
Numerous studies suggest that HSC with LTRC activity reside within the hematopoietic stem cell niche at the bone marrow endosteum. [78] [79] [80] [81] In fact, a recent paper suggests that compared with HSC in the central regions of the marrow, HSC isolated from the endosteal region exhibit 2-fold greater proliferation and homing capacity and significantly enhanced hematopoietic reconstitution potential. 82 However, studies defining HSC using SLAM markers suggest that the central marrow region contains large numbers of HSC capable of long-term repopulation. 83 While mobilization of endosteal HSC with enhanced reconstitution potential by G-CSF is possible, given the multiday dosing requirement, the capacity of GROb or CXCR4 agonists or antagonists to mobilize LTR-HSC within 15-60 min appears kinetically inconsistent with endosteal stem-cell mobilization, and more consistent with mobilization from the vascular niche.
The superiority of GROb-mobilized stem cells compared to G-CSF-mobilized stem cells for transplantation once again raises questions of the quality of the stem cells. We have extensively characterized HSC and HPC phenotype and function of GRObmobilized LDMC and compared them to cells mobilized by G-CSF (Figure 2 ). Stem cells mobilized by GROb show significantly lower levels of apoptosis than cells mobilized by G-CSF. Since stem cell survival contributes to homing and it is known that G-CSF-mobilized CD34 þ cells express higher levels of caspases and Annexin V than resident marrow CD34 þ cells, 84 lower apoptosis in GROb-mobilized cells likely contributes to their enhanced engraftment. GROb-mobilized HPC and HSC display significantly reduced migration to SDF-1 in vitro compared to cells mobilized by G-CSF; however, they show significantly enhanced homing to bone marrow in vivo. Lack of correlation between in vitro migration to SDF-1 and marrow homing of G-CSF plus AMD3100-mobilized CD34 þ cells has also been reported. 67 No difference in surface expression of CXCR4 is observed between GROb or G-CSF-mobilized cell populations, although GROb-mobilized cells contain lower levels of intracellular CXCR4 than G-CSF-mobilized cells. Nevertheless, alteration in CXCR4 receptor levels is unlikely a cause of reduced in vitro migration by GROb-mobilized cells. Homing of G-CSF-mobilized SKL cells, or marrow SKL cells, 77 could be significantly inhibited by pretreatment of cells with 10 mM AMD3100, however this had no effect on homing of GRObmobilized SKL cells, further supporting independence from the SDF-1/CXCR4 receptor axis. Static expression of adhesion molecules CD62 (L-Selectin, LCECAM-1), CD49d (a4 integrin), CD49e (a5 integrin) or CD11a (aL integrin, LFA-1) were equivalent between the mobilized populations, however, GROb-mobilized KL and SKL cells demonstrated enhanced adherence to VCAM-1 and C166 mouse stromal cells, suggesting expression of more activated adhesion receptors. CD26 expression on GROb-mobilized SKL cells was significantly higher than on G-CSF-mobilized cells and the GROb-mobilized LDMC population contains twice the number of CD26 Pos SKL cells compared to G-CSF.
Based upon function and immunophenotype, the GRObmobilized cell population contains HPC and HSC with enhanced homing and engraftment capacity, enhanced adhesion properties and better overall survival. In addition, the facts that they home to marrow more efficiently in vivo despite poor migration response to SDF-1a in vitro; home equally well in the absence and presence of the CXCR4 antagonist AMD3100 and express high levels of CD26, which is believed to degrade SDF-1 and interfere with HSC homing, suggests that the homing/ engraftment/trafficking of GROb-mobilized HSC is less dependent on the SDF-1/CXCR4 axis. This is in contrast with G-CSFmobilized cells that display enhanced migration to SDF-1 compared to marrow, low CD26 expression and marrow homing that is selectin and integrin independent. 58 The finding of a disconnect between in vitro migration to SDF1a and homing and engraftment of GROb-mobilized HSPC is contrary to the hypothesis that the SDF-1/CXCR4 axis is the primary axis involved in HSPC trafficking, engraftment and mobilization. 61, [85] [86] [87] Additional reports that WBC recovery is faster in patients transplanted with G-CSF-mobilized PBSC than bone marrow cells, 88, 89 that G-CSF-mobilized CD34 þ cells migrate less well to SDF-1a in vitro than marrow CD34 þ cells, 70, 90 that inhibition of Gai-coupled receptors, which includes CXCR4, by Pertusis toxin does not impair hematopoietic engraftment, 91 that fetal liver cells from CXCR4 À/À mice home and engraft in lethally irradiated recipients, 92 and that marrow engraftment of CXCR4 À/À and CXCR4 þ / þ SKL cells is equivalent 93 also suggest that the SDF-1a/CXCR4 axis may not be absolutely required for engraftment and homing by all HSC populations. Moreover, homing of HPC refractory to SDF-1 migration is blocked in the absence of a4-integrins, indicating that homing via SDF-1a/CXCR4 can be fully compensated by a functional a4-integrin/VCAM-1 pathway. 94 The enhanced adhesion properties displayed by these GROb-mobilized cells would be consistent with primary reliance on the integrin pathway for homing and engraftment.
Utility of chemokine axis-mobilization
It is clear that chemokine axis and G-CSF-mobilized peripheral blood contain hematopoietic stem cell populations with different functional properties. The enhanced engrafting properties of chemokine axis mobilized PBSC may have several distinct advantages for clinical utility. Enhanced homing properties suggest that these cells may have greater therapeutic utility in combination with appropriate gene transduction technologies for treatment of genetic or inherited metabolic diseases. Rapid mobilization may be an attractive paradigm for PBSC transplantation, alone or in combination with G-CSF, to reduce the duration of the standard G-CSF regimen or to increase cell yield, in difficult-to-mobilize patients. In mouse studies combination GROb plus G-CSF 95 and AMD3100 plus G-CSF 67, 95 regimens enhanced mobilization in FancC knockout mice that respond poorly to G-CSF alone. Mobilization with G-CSF plus AMD3100 in clinical trials resulted in more patients achieving sufficient PBSC for transplant than with G-CSF alone. 96 It is tempting to speculate that combination chemokine axis mobilization, for example, with GROb and AMD3100, may lead to single collections in most normal and patient populations.
The emerging role of marrow as a reservoir for adult stem cell populations able to contribute to tissue repair/regeneration raises the question of utility of the chemokine mobilization axis to mobilize stem cell types other than hematopoietic stem cells and/or to rapidly mobilize regenerative stem cells in the acute injury setting. Several cytokines have been implicated in angiogenic cell mobilization including VEGF, Angiopoietin-1, placental growth factor and G-and GM-CSF.
97-100 G-CSF has been shown to mobilize endothelial progenitor cells in a number of animal models. 97, [101] [102] [103] However, the kinetics of mobilization may likely preclude utility for acute vascular repair. We have observed mobilization of endothelial stem and progenitor cells by GROb in mice.
73 AMD3100 has been shown to increase EPC in mobilized blood that can be efficiently collected and stored. 104 Adenoviral delivered hSDF-1a can mobilize bone marrow-derived endothelial stem cells. 105 The ability of chemokines to mobilize endothelial stem cells and the rapidity of mobilization observed via the chemokine axis, suggest that this axis may have utility in mobilizing stem cells for vascular repair. Further characterization studies on the adult stem cell content of mobilized blood may identify other therapeutic potentials for these cells. neg cells were subjected to in vitro migration to 100 ng ml À1 rmSDF-1 for 4 h. Input and migrated cells were collected, washed and CFU-GM enumerated in 1% methylcellulose with 30% FBS, 1 U ml À1 rhEpo, 10 ng ml À1 rmGM-CSF and 50 ng ml À1 rmSCF or stained with anti-c-kit and anti-Sca-1 and migrating cells analyzed by flow cytometry. PBMC mobilized by G-CSF or GROb were stained with 5 mM 5-(and 6-) carboxyfluorescein diacetate succinimidyl ester (CFSE) and 4 Â 10 7 cells transplanted into lethally irradiated syngeneic recipients. Recipient marrow cells were harvested 16 h after transplantation. Total KL or SKL cells homed to marrow were calculated as: (% CFSE þ KL or SKL cells in recipient marrow) Â 100 À1 Â (% CFSE þ cells in recipient marrow) Â 100 À1 Â (total nucleated recipient marrow cells recovered) Â (100/ 30), assuming marrow cells from two femurs, two tibias, two humerus and the pelvis represents 30% of total body marrow. Percent homing was determined as (KL or SKL cells homed to the marrow)C(KL or SKL cells transplanted) Â 100 in each recipient and the data were averaged. In some experiments (see inset) CFSE-stained lin neg cells were pretreated with 10 mM AMD3100 or PBS for 15 min at 37 1C, washed and transplanted, to determine the effect of CXCR4 antagonism on homing. Surface KL and SKL cell CXCR4 expression was evaluated on lin neg cells using anti Fc-gIII/II block and anti-CXCR4. Intracellular CXCR4 in mobilized KL and SKL cells was determined by staining lin neg cells with FITC-Sca-1, APC-c-kit and a saturating amount of nonconjugated anti-mouse CXCR4. Cells were fixed with 1% paraformaldehyde, permeabilized with 0.25% Triton X/0.5% BSA/PBS and stained with PE-CXCR4. Mobilized PBMC in 0.5% BSA/RPMI-1640 (4 Â 10 4 cells per well) were added to plates precoated with 5 mg ml À1 human fibronectin or fibronectin plates seeded with C166 cells 48 h prior to adhesion assays. The plates were briefly centrifuged to facilitate adhesion. After 30 min at 37 1C, wells were washed and non-adherent cells collected. Input cells and non-adherent KL and SKL cells were quantitated and percent adhesion determined by subtracting % non-adherent cells from 100. Surface expression of CD62, CD49d, CD11a, CD49e and CD26 was analyzed on lin neg cells blocked with anti Fc-gIII/II block using specific antibodies (MEL14; 9C10; 2D7; 5H10-27; H194-112; all from BD Biosciences). CD26 expression on SKL cells was quantitated following staining of lin neg cells with PE-Sca-1, APC-c-kit and FITC CD26. *Po0.05.
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